Immunoinflammatory responses in gastrointestinal tract injury and recovery

• Autorzy: Verma G. , Marella A. , Shaquiquzzaman M. , Alam M. M.
• Języki publikacji: EN

Abstrakty

EN

 Inflammation is a non-specific immune response to infection, irritation or other injury, the key features being redness, warmth, swelling and pain. A number of mediators are released which alter the resistance of mucosa to injury induced by noxious substances. Oxidative stress is a unifying mechanism of injury in many types of disease processes, including gastrointestinal diseases. It has been defined as an imbalance in the activity of pro and antioxidants. Pro-oxidants favour free radical formation while antioxidants inhibit or retard the same. A number of markers of oxidative stress have been identified. This review provides an overview of various mediators of inflammation and oxidative stress, and diverse approaches for prevention and treatment of gastrointestinal inflammation.

Słowa kluczowe

EN

immunoinflammatory response; gastrointestinal tract; injury; recovery; oxidative stress; inflammation; infection; gastrointestinal disease

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2013
• Tom: 60
• Numer: 2
• Opis fizyczny: p.143-149,fig.,ref.

Twórcy

autor

Verma G.

• Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India

autor

Marella A.

• Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India

autor

Shaquiquzzaman M.

• Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India

autor

Alam M. M.

• Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India

Bibliografia

• Andoh A, Fujiyama Y (2006) Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. World J Gastroenterol 12: 4452-4460. 
• Aw TY (1999) Molecular and cellular responses to oxidative stress and changes in oxidation-reduction imbalance in the intestine. Am J Clin Nutr 70: 557-565. 
• Barrachina MD, Panes J, Esplugues JV (2001) Role of nitric oxide in gastrointestinal inflammation and ulcerative diseases: perspective for drugs development. Curr Pharm Design 7: 31-48. 
• Bhardwaj P (2008) Oxidative stress and antioxidants in gastrointestinal diseases. Trop Gastroenterol 29: 129-135. 
• Bonnans C, Vachier I, Chavis C, Godard P, Bousquet J, Chanez P (2002) Lipoxins are potential endogenous anti-inflammatory mediators in asthma. Am J Resp Crit Care 165: 1531-1535. 
• Brenchley JM, Douek DC (2012) Microbial translocation across the GI tract. Annu Rev Immunol 30: 149-173. 
• Brzozowski T, Konturek PC, Pajdo R, Ptak-Belowska A, Kwiecien S, Pawlik M, Drozdowicz D, Sliwowski Z, Brzozowski B, Konturek SJ, Pawlik WW (2008) Physiological mediators in non Steroidal anti-inflammatory drugs (NSAIDs) induced impairment of gastric mucosal defense and adaptation-focus on nitric oxide and lipoxins. J Physiol Pharmacol 59: 89-102. 
• Chaitanya GV, Franks SE, Cromer W, Wells SR, Bienkowska M, Jennings MH, Ruddel A, Ando T, Wang Y, Gu Y, Sapp M, Mathis JM, Jordan PA, Minagar A, Alexander JS (2010) Differential cytokine responses in human and mouse lymphatic endothelial cells to cytokines in vitro. Lymphatic Res Biol 8: 155-164. 
• Coruzzi G, Venturi N, Spaggiari S (2007) Gastrointestinal safety of novel non steroidal anti- inflammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed 78: 96-110. 
• Culligan EP, Hill C, Sleator RD (2009) Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog 1: 19. 
• DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC (2002) Intestinal permeation and gastrointestinal Disease. J Clin Gastroenterol 34: 385-396. 
• Di Carlo G, Izzo AA (2003) Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs 12: 39-49. 
• Dovhanj J, Svagelj Drazen (2011) Oxidative stress pathway driven by inflammation in gastric mucosa. Gastritis and Gastric Cancer New Insights in Gastroprotection Diagnosis and Treatment ISBN: 978-953-307-375-0: 47-62.
• Gill HS, Guarner F (2004) Probiotics and human health: a clinical perspective. Postgrad Med J 80: 516-526. 
• Gionchetti P, Rizzello F, Campieri M (2002) Probiotics in gastroenterology. Curr Opin Gastroenterol 18: 235-239. 
• Grisham MB, Von RC, Smith BF, Lamont JT, Granger DN (1987) Interaction between oxygen radicals and gastric mucin. Am J Physiol 253: G93-G96. 
• Guarner F (2007) Prebiotics in inflammatory bowel disease. Br J Nutr 98: S85-S89. 
• Hawkey CJ, Langman CJ (2003) Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52: 600-608. 
• Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J. Cancer 121: 2373-2380. 
• Isolauri E, Kirjavainen P, Salminen S (2002) Probiotics: a role in treatment of intestinal infection and inflammation. Gut 50: iii54-iii59. 
• Johnson LR, McCormack SA (1999) Healing of gastrointestinal mucosa: involvement of polyamines. News Physiol Sci 14: 12-17. 
• Jourd'heuil D, Grisham MB, Granger DN (1999) Nitric oxide and the gut. Curr Gastroenterol Rep 1: 384-388. 
• Kim YJ, Kim EH, Hahm KB (2012) Oxidative stress in inflammation based gastrointestinal tract diseases. J Gastroenterol Hepatol 27: 1004-1010. 
• Kubes P, McCafferty DM (2000) Nitric oxide and intestinal inflammation. Am J Med 109: 150-158. 
• Kubes P, Wallace J L (1995) Nitric oxide as a mediator of gastrointestinal mucosal injury?-Say it ain't so. Mediators Inflamm 4: 397-405. 
• Kvietys PR, Granger DN (2012) Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic Biol Med 52: 556-592. 
• Lamprecht M, Bogner S, Schippinger G, Steinbauer K, Fankhauser F, Hallstroem S, Schuetz B, Greilberger JF (2012) Probiotic supplementation affects markers of intestinal barrier, oxidation and inflammation in trained men, a randomized double blinded, placebo controlled trial. J Internat Soc Sports Nutr 9: 45-58. 
• Lanas A (2010) A review of the gastrointestinal safety data-i-a gastroenterologist's perspective. Rheumatology 49: ii3-ii10. 
• Lichtenberger LM, Barron M, Marathi U (2009) Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today 45: 877-890. 
• Macdonald LJ, Boddy SC, Denison FC, Sales KJ, Jabbour HN (2011) A role for lipoxin A4 as an anti-inflammatory mediator in the human endometrium. Reproduction 142: 345-352. 
• Martin GR, Wallace JL (2006) Gastrointestinal inflammation: a central component of mucosal defense and repair. Exp Biol Med 231: 130-137. 
• Medilexicon's Medical Dictionary.
• Nahoum SR (2006) Why cancer and inflammation. Yale J Biol Med 79: 123-130. 
• Naito Y (2006) Oxidative stress in digestive diseases. J Clin Biochem Nutr 39: 55.
• Neerudu M, Rajababu, Reddy H, Koppolu P (2009) Antiinflammatory mediators. IJDA 2: 182-184.
• Ock CY, Kim EH, Choi DJ, Lee HJ, Hahm KB, Chung MH (2012) 8-Hydroxydeoxyguanosine: not mere biomarker for oxidative stress, but remedy for oxidative stress implicated gastrointestinal diseases. World J Gastroenterol 18: 302-308. 
• Olyaee M, Sontag S, Salman W, Schnell T, Mobarhan S, Eiznhamer D, Keshavarzian A (1995) Mucosal Reactive Oxygen Species in oesophagitis and barrett's oesophagus. Gut 37: 168-173. 
• Parvez S, Malik KA, Ah KS, Kim HY (2006) Probiotics and their fermented food products are beneficial for health. J Appl Microbiol 100: 1171-1185. 
• Pathmakanthan S, Hawkey C (2000) A lay doctor's guide to inflammatory process in the gastrointestinal tract. Postgrad Med J 76: 611-617. 
• Rea WJ, Patel K (2010) Regulating mechanisms of chemical sensitivity. Reversibility of Chronic Degenerative Disease and Hypersensitivity 1: 337-417.
• Reddy EP, Reddy VS, Chandra MK, Rao PVLNS (2010) Physiological antioxidant system and oxidative stress in stomach cancer patients with normal renal and hepatic function. Online J Health Allied Scs 8: 9-12.
• Reimund JM, Tavernier M, Veinnot S, Hussein IAH, Dupont B, Justum AM, Jurjus AR, Freund JN, Lecheverel M (2012) Ulcerative colitis associated colorectal prevention by 5-aminosalicylates: current status and perspectives. Ulcerative Colitis from Genetics to Complications 149-166.
• Rial E, Zardoya R (2009) Oxidative stress, thermogenesis and evolution of uncoupling proteins. J Biol 8: 58-58.5. 
• Ricciotti E, Fitz GG (2011) Prostaglandins and inflammation. Arterioscl Throm Vasc Biol 31: 986-1000. 
• Scandalios JG (2005) Oxidative stress: molecular perception and transduction of signals triggering antioxidant gene defenses. Braz J Med Biol Res 38: 995-1014. 
• Stankov SV (2012) Definition of inflammation, causes of inflammation and possible anti-inflammatory strategies Open Inflammation J 5: 1-9.
• Sunkara S, Swanson G, Forsyth CB, Keshavarzian A (2011) Chronic inflammation and malignancy in ulcerative colitis. Ulcers 2011: 1-9.
• Tolstanova G, Deng X, French SW, Lungo W, Paunovic B, Khomenko T, Ahluwalia A, Kaplan T, Dacosta IM, Tarnawski A, Szabo S, Sandor Z (2012) Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice. Lab Invest 92: 9-21. 
• Triantafillidis JK, Nasioulas G, Kosmidis PA (2009) Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 29: 2727-2737. 
• Vanderhoof JA, Young RJ (2001) The role of probiotics in treatment of intestinal infections and inflammation. Curr Opin Gastroenterol 17: 58-62. 
• Verma AK, Verma R, Paul J (2007) Role of gut flora in inflammatory bowel disease - a state of art. Communicating Current Research and Educational Topics and Trends in Applied Microbiology 705-718.
• Wallace JL, Chin BC (1997) Inflammatory mediators in gastrointestinal defense and injury. Proc Soc Exp Biol Med 214: 192-203. 
• Wallace JL, Granger DN (1996) The cellular and molecular basis of gastric mucosal defense. FASEB J 10: 731-740. 
• Wallace JL, Vong L (2008) NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs. Curr Opin Investig Drugs 9: 1151-1156